Table 1.
Cohort Characteristics (N = 360)
| Recipient age, years (IQR, range) | 53 (44–60, 20–71) |
| Male gender [n (%)] | 268 (74.4) |
| Indication for HT [n (%)] | |
| Dilated cardiomyopathy | 141 (39.2) |
| Ischemic cardiomyopathy | 134 (37.2) |
| Valvular cardiomyopathy | 24 (6.7) |
| Hypertrophic cardiomyopathy | 23 (6.4) |
| Adriamycin-induced cardiomyopathy | 18 (5.0) |
| Congenital heart disease | 5 (1.4) |
| Restrictive heart disease | 4 (1.1) |
| Othera | 11 (3.1) |
| Induction immunosuppression [n (%)] | |
| Methylprednisolone alone | 272 (75.6) |
| Methylprednisolone and OKT3/daclizumab/ATG | 88 (24.4) |
| Cytomegalovirus disease post-transplant [n (%)] | 10 (2.8) |
| ≥1 episode of acute cellular rejection post- transplant [n (%)] | 148 (41.1) |
| Pre-operative VAD [n (%)] | 134 (37.2) |
| Reoperation within 10 days of HT [n (%)] | 106 (29.4) |
| Delayed chest closure [n (%)] | 86 (23.9) |
| Peri-operative VAD placement [n (%)] | 17 (4.7) |
| Post-operative hemorrhage [n (%)] | 16 (4.4) |
| Other [n (%)]b | 3 (0.8) |
ATG, anti-thymocyte globulin; HT, heart transplant; IQR, interquar-tile range; VAD, ventricular assist device.
a
Arrhythmogenic right ventricular cardiomyopathy (3), acute viral myocarditis (3), amyloidosis (3) or giant cell myocarditis (2).
b
Reoperation for post-HT pneumomediastinum/air leak (1), abdominal dehiscence (1) or placement of an extracorporeal membrane oxygenation circuit (1).